Cystic Fibrosis, Glucose Metabolism Disorders
Conditions
Keywords
Cystis Fibrosis, Glucose intolerance, Glargine, FEV1%
Brief summary
Glargine treatment can improve the clinical features in Cystic Fibrosis patients affected by glucose derangements
Detailed description
To evaluate the effect of glargine treatment on BMI, lung function, acute pulmonary infections and HbA1c in cystic fibrosis (CF) patients with different glucose derangements, eighty-seven patients were screened for glucose derangements with fasting hyperglycaemia or abnormalities at the oral glucose tolerance test. They were classified on the basis of a gluco-score ranging 0-5. Patients with gluco-score \> 1 were treated with glargine. We report on the results of the first 20 patients who completed 12 months of treatment. BMI z-score, forced expiratory volume in the first second (FEV1), number of acute lung infections in the previous year and HbA1c were the study outcomes.
Interventions
DRUGGlargine
Sponsors
Federico II University
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
3 Years to 20 Years
Healthy volunteers
No
Inclusion criteria
* Patients affected by Cystic Fibrosis who had shown glucose derangements.
Exclusion criteria
* Patients with/without Cystic Fibrosis without glucose derangements.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction of decline in pulmonary function measured as FEV1 | One year |
Secondary
| Measure | Time frame |
|---|---|
| Improvement of: Body Mass Index, Number of Lung Infections, HbA1c | One Year |
Countries
Italy
Outcome results
None listed